Le Point : Disease of the retina: progress in view
Scientific research and high technology now allow the blind and partially sighted to recover some of their lost sense.
Scientific research and high technology now allow the blind and partially sighted to recover some of their lost sense.
After
announcing in September 2018 the successful activation of its subretinal photovoltaic
implant in 5 French patients with dry AMD, Pixium Vision presented the results
of its feasibility study at a conference in early March.
In
September 2018, 5 patients with advanced atrophic dry AMD received the new generation
PRIMA subretinal implant. Six months later, all had preserved their peripheral
vision, and all are able to perceive light signals from central area.
There were 445 entries in the #LetsgoFrance competition, then 64 semi-finalists. Thanks to the votes of PwC’s 5,000 employees, they are now only 19! Revealed this week in Forbes magazine, the 19 finalists of the #LetsgoFrance Trophies are now preparing for the pitch before the Grand Jury.
The 11th World Congress on the Relationship between Neurobiology and Nano-Electronics Focusing on Artificial Vision.Venue : The Henry hotel, Dearborn Michigan, from 10 to 12 november 2019.
The 19th congress of European Retina, Macula and Vitreous Society (EURETINA) will take place from 5 – 8 Sept at at the Palais des Congrès in Paris, France. The congress touches on fields like Retina, Eyesight, Medical, Healthcare and Ophthalmology. The Annual Congress programme will have a clinical focus and include topics such as AMD, Vitreoretinal Surgery, Imaging, Uveitis/Inflammation, Diabetes and Retinal Vascular Disease.
Welcome to the HealthTech Investor Day® by FranceBiotech,under the High Patronage of Mr Emmanuel MACRON President of the French Republic.
For the first time, France Biotech(The French Association of French HealthTech Entrepreneurs) is organizing a one-on-one meetings event to connect leading international investors, pharmaceutical companies and European top management innovative companies in HealthTech.
Why MaculArt? Because of the beauty of macular imaging, because of our daily enthusiasm for management of macular disorders, because our field is in permanent renewal and full of innovations, the field of medical macula can be considered as an Art.Ophthalmologists from around the globe will be present to share their knowledge and discuss major advances in our field. The scientific program of MaculArt include clinical case sessions, poster sessions, free paper sessions, and 14 faculty sessions…